MaxCyte Updates 2025 Revenue Guidance to $29.5M-$32.5M Amid Customer Program Consolidation

MaxCyte has revised its 2025 core revenue guidance to $29.5M-$32.5M due to customer program consolidation. In Q2 2025, the company reported financial results in line with expectations and highlighted growth in a challenging end market, as well as the signing of two new strategic platform agreements.

MaxCyte, Inc. (MXCT), a leading cell-engineering focused company, has revised its 2025 core revenue guidance to $29.5 million to $32.5 million due to customer program consolidation. The company reported financial results for the second quarter of 2025 in line with expectations, demonstrating growth in a challenging end market. Additionally, MaxCyte highlighted the signing of two new strategic platform agreements [2].

During the second quarter of 2025, MaxCyte's core business revenue reached $8.2 million, an increase of 8% over the second quarter of 2024. The company's total revenue for the period was $8.5 million, a decrease of 18% compared to the second quarter of 2024. This decline was primarily due to the timing variability of SPL Program-related revenue milestones and royalties. The company added two new SPL clients, Adicet Bio and Anocca AB, in July, and also signed TG Therapeutics in the first quarter [2].

MaxCyte's strategic focus on expanding its platform technology's reach and advancing cell therapeutics continues to drive its growth. The company's revised guidance reflects its ongoing efforts to consolidate customer programs and capitalize on market opportunities. As the cell engineering sector evolves, MaxCyte's platform technologies remain a key enabler for the discovery, development, and commercialization of next-generation cell therapeutics [2].

References:

[1] https://seekingalpha.com/news/4480980-veracyte-raises-2025-revenue-guidance-to-504m-as-decipher-volumes-surge-and-strategic
[2] https://www.globenewswire.com/news-release/2025/08/06/3128677/0/en/MaxCyte-Reports-Second-Quarter-2025-Financial-Results-and-Updates-Full-Year-2025-Guidance.html